The DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.
Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections
Open accessAbstract
SUMMARY: The entry of anti-infectives into the central nervous system (CNS) depends on the compartment studied, molecular size, electric charge, lipophilicity, plasma protein binding, affinity to active transport systems at the blood-brain/blood-cerebrospinal fluid (CSF) barrier, and host factors such as meningeal inflammation and CSF flow. Since concentrations in microdialysates and abscesses are not frequently available for humans, this review focuses on drug CSF concentrations. The ideal compound to treat CNS infections is of small molecular size, is moderately lipophilic, has a low level of plasma protein binding, has a volume of distribution of around 1 liter/kg, and is not a strong ligand of an efflux pump at the blood-brain or blood-CSF barrier. When several equally active compounds are available, a drug which comes close to these physicochemical and pharmacokinetic properties should be preferred. Several anti-infectives (e.g., isoniazid, pyrazinamide, linezolid, metronidazole, fluconazole, and some fluoroquinolones) reach a CSF-to-serum ratio of the areas under the curves close to 1.0 and, therefore, are extremely valuable for the treatment of CNS infections. In many cases, however, pharmacokinetics have to be balanced against in vitro activity. Direct injection of drugs, which do not readily penetrate into the CNS, into the ventricular or lumbar CSF is indicated when other effective therapeutic options are unavailable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
JUNCTIONAL COMPLEXES IN VARIOUS EPITHELIA
Farquhar, M. G., & Palade, G. E. (1963) · The Journal of Cell Biology · doi:10.1083/jcb.17.2.375 · Cited by 3,635
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
FINE STRUCTURAL LOCALIZATION OF A BLOOD-BRAIN BARRIER TO EXOGENOUS PEROXIDASE
Reese, T. S., & Karnovsky, M. J. (1967) · The Journal of Cell Biology · doi:10.1083/jcb.34.1.207 · Cited by 2,629 · cited 1×
“, inulin (201) and horseradish peroxidase (27), showed that the morphological correlate of the blood-brain barrier are the cells of the cerebrovascular endothelium linked by tight junctions (203).”
BackgroundJUNCTIONS BETWEEN INTIMATELY APPOSED CELL MEMBRANES IN THE VERTEBRATE BRAIN
Brightman, M. W., & Reese, T. S. (1969) · The Journal of Cell Biology · doi:10.1083/jcb.40.3.648 · Cited by 2,471
Practice Guidelines for the Management of Bacterial Meningitis
Tunkel, A. R., Hartman, B. J., Kaplan, S. L., Kaufman, B. A., Roos, K. L., Scheld, W. M., & Whitley, R. J. (2004) · Clinical Infectious Diseases · doi:10.1086/425368 · Cited by 2,308 · cited 1×
“pneumoniae meningitis are scarce, some authors recommended that in areas with high rates of occurrence of penicillin-resistant pneumococcal strains, the combination of ceftriaxone plus rifampin instead of vancomycin should be preferred, or rifampin, vancomycin, and ceftriaxone should be administered together when adju…”
BackgroundSchinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929
P-Glycoprotein, a gatekeeper in the blood–brain barrier
Schinkel, A. H. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00085-4 · Cited by 960
Blood-brain barrier active efflux transporters: ATP-binding cassette gene family
Löscher, W., & Potschka, H. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.86 · Cited by 872
Pharmacokinetic issues for antibiotics in the critically ill patient
Roberts, J. A., & Lipman, J. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181961bff · Cited by 862
Cited by
Alzheimer's Disease: Treatment Strategies and Their Limitations.
Passeri, E., Elkhoury, K., Morsink, M., Broersen, K., Linder, M., Tamayol, A., Malaplate, C., Yen, F. T., & Arab-Tehrany, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213954 · Cited by 689
“This discovery was later confirmed by his student Edwin Goldman in 1913 [190].”
BackgroundGut microbiota and the neuroendocrine system
Farzi, A., Fröhlich, E. E., & Holzer, P. (2018) · Neurotherapeutics · doi:10.1007/s13311-017-0600-5 · Cited by 478
Multifunctional nanoparticles for brain tumor imaging and therapy
Cheng, Y., Morshed, R. A., Auffinger, B., Tobias, A. L., & Lesniak, M. S. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.006 · Cited by 349
Advances in treatment of bacterial meningitis
van de Beek, D., Brouwer, M. C., Thwaites, G. E., & Tunkel, A. R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61186-6 · Cited by 336
Marizzoni, M., Cattaneo, A., Mirabelli, P., Festari, C., Lopizzo, N., Nicolosi, V., Mombelli, E., Mazzelli, M., Luongo, D., Naviglio, D., et al. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200306 · Cited by 333
Stimuli-responsive In situ gelling system for nose-to-brain drug delivery
Agrawal, M., Saraf, S., Saraf, S., Dubey, S. K., Puri, A., Gupta, U., Kesharwani, P., Ravichandiran, V., Kumar, P., Naidu, V. G. M., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.044 · Cited by 298
Koopmans, M. M., Brouwer, M. C., Vázquez-Boland, J. A., & van de Beek, D. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00060-19 · Cited by 293
Acute bacterial meningitis in adults
McGill, F., Heyderman, R. S., Panagiotou, S., Tunkel, A. R., & Solomon, T. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30654-7 · Cited by 274
Harris, S. A., & Harris, E. A. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142853 · Cited by 279
“This in turn results in increased A PP processing, A accumulation, further BBB permeability, and infiltration of more T cells, leading to a continuous cycle of neurodegeneration (Fig.”
BackgroundInfluentialKetogenic diet modifies the gut microbiota in a murine model of autism spectrum disorder
Newell, C., Bomhof, M. R., Reimer, R. A., Hittel, D. S., Rho, J. M., & Shearer, J. (2016) · Molecular Autism · doi:10.1186/s13229-016-0099-3 · Cited by 272
Gene Therapy Tools for Brain Diseases
Ingusci, S., Verlengia, G., Soukupova, M., Zucchini, S., & Simonato, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00724 · Cited by 158
Targeting innate immunity for neurodegenerative disorders of the central nervous system
Andreasson, K. I., Bachstetter, A. D., Colonna, M., Ginhoux, F., Holmes, C., Lamb, B., Landreth, G., Lee, D. C., Low, D., Lynch, M. A., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13667 · Cited by 126
Fail-Safe System against Potential Tumorigenicity after Transplantation of iPSC Derivatives
Itakura, G., Kawabata, S., Ando, M., Nishiyama, Y., Sugai, K., Ozaki, M., Iida, T., Ookubo, T., Kojima, K., Kashiwagi, R., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.02.003 · Cited by 115
Sankowski, B., Księżarczyk, K., Raćkowska, E., Szlufik, S., Koziorowski, D., & Giebułtowicz, J. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.10.038 · Cited by 105
Antibiotics and the nervous system: More than just the microbes?
Champagne-Jorgensen, K., Kunze, W. A., Forsythe, P., Bienenstock, J., & McVey Neufeld, K.-A. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.12.014 · Cited by 92
Nizzardo, M., Nardini, M., Ronchi, D., Salani, S., Donadoni, C., Fortunato, F., Colciago, G., Falcone, M., Simone, C., Riboldi, G., et al. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.01.017 · Cited by 64
Rossi, S. A., de Oliveira, H. C., Agreda-Mellon, D., Lucio, J., Mendes-Giannini, M. J. S., García-Cambero, J. P., & Zaragoza, O. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01921-19 · Cited by 48
Challenges of Repurposing Tetracyclines for the Treatment of Alzheimer’s and Parkinson’s Disease
Markulin, I., Matasin, M., Turk, V. E., & Salković-Petrisic, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02457-2 · Cited by 36
Bodilsen, J., Larsen, L., Brandt, C. T., Wiese, L., Hansen, B. R., Andersen, C. Ø., Lüttichau, H. R., Helweg-Larsen, J., Storgaard, M., & Nielsen, H. (2021) · Clinical Epidemiology · doi:10.2147/clep.s326461 · Cited by 33
Antibiotic therapy for adults with neurosyphilis
Buitrago-Garcia, D., Martí-Carvajal, A. J., Jimenez, A., Conterno, L. O., & Pardo, R. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011399.pub2 · Cited by 30
Djukic, M., Lange, P., Erbguth, F., & Nau, R. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02538-3 · Cited by 25
Self-citationBretonnière, C., Jozwiak, M., Girault, C., Beuret, P., Trouillet, J.-L., Anguel, N., Caillon, J., Potel, G., Villers, D., Boutoille, D., et al. (2015) · Critical Care · doi:10.1186/s13054-015-1021-7 · Cited by 24
Zamora, G. M., Wang, F., Sun, C.-H., Trinidad, A., Kwon, Y. J., Cho, S. K., Berg, K., Madsen, S. J., & Hirschberg, H. (2014) · Journal of Biomedical Optics · doi:10.1117/1.jbo.19.10.105009 · Cited by 21
“The three most important are the blood brain barrier, the blood–cerebrospinal fluid barrier, and the blood–tumor barrier.(24,25) The latter, caused by the leaky tumor vasculature, results in high intratumoral interstitial pressure (edema), which severely limits drug penetration from the bloodstream into the tumor.”
Zhang, W., Oh, J.-H., Zhang, W., Rathi, S., Le, J., Talele, S., Sarkaria, J. N., & Elmquist, W. F. (2023) · Pharmaceutical Research · doi:10.1007/s11095-023-03574-1 · Cited by 19
“While it is recognized that there are additional barriers in the CNS, such as the blood-CSF barrier [16–18], and the arachnoid barrier [19, 20], the current review focuses on the influence of the BBB.”
Amaral, L. D., Santos, N. A. G. D., Sisti, F. M., Del Bel, E., & Santos, A. C. D. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109454 · Cited by 18
Schiave, L. A., Nascimento, E., Vilar, F. C., de Haes, T. M., Takayanagui, O. M., Gaitani, C. M. D., & Martinez, R. (2018) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2017.10.003 · Cited by 15
Metadata
- Authors
- Nau, R., Sörgel, F., & Eiffert, H.
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 2010-10
- Volume
- 23
- Issue
- 4
- Pages
- 858-883
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- OpenAlex
- W2140603169
- Cited by
- 1,026
- References
- 151
- FWCI
- 12.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.